⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8492320 | 0.92 | — | — | |
| SCHEMBL8490869 | 0.90 | — | — | |
| SCHEMBL12489954 | 0.85 | — | — | |
| SCHEMBL8585822 | 0.83 | GPR52 (0.35) | — | |
| SCHEMBL7846190 | 0.81 | KEAP1 (0.41) | — | |
| SCHEMBL6457920 | 0.80 | HRH1 (0.37) | — | |
| SCHEMBL6958918 | 0.80 | TDP1 (0.34) | — | |
| SCHEMBL7375911 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL9531437 | 0.79 | — | — | |
| SCHEMBL7842985 | 0.79 | AKR1B1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0625155-B1 | PYRROLOIMIDAZOLYL AND IMIDAZOPYRIDINYL SUBSTITUTED 1H-BENZIMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2001-08-08 | — | — | EP | disclosed |
| WO-1999005114-A2 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |